Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Orthopaedic Surgery and Research
Published in: Journal of Orthopaedic Surgery and Research 1/2017

Open Access 01-12-2017 | Review

Pathogenesis and potential relative risk factors of diabetic neuropathic osteoarthropathy

Authors: Hong-Mou Zhao, Jia-Yu Diao, Xiao-Jun Liang, Feng Zhang, Ding-Jun Hao

Published in: Journal of Orthopaedic Surgery and Research | Issue 1/2017

Login to get access

Abstract

Diabetic neuropathic osteoarthropathy (DNOAP) is an uncommon, but with considerable morbidity and mortality rates, complication of diabetes. The real pathogenesis is still unclear. The two popular theories are the neuro-vascular theory and neuro-traumatic theory. Most theories and pathways focused on the uncontrolled inflammations that resulted in the final common pathway, receptor activator of nuclear factor κβ ligand (RANKL)/osteoprotegerin (OPG) axis, for the decreased bone density in DNOAP with an osteoclast and osteoblast imbalance. However, the RANKL/OPG pathway does not explain all the changes, other pathways and factors also play roles. A lot of DNOAP potential relative risk factors were evaluated and reported in the literature, including age, gender, weight, duration and type of diabetes, bone mineral density, peripheral neuropathy and arterial disease, trauma history, and some others. However, most of them are still in debates. Future studies focus on the pathogenesis of DNOAP are still needed, especially for the genetic factors. And, the relationship between DNOAP and those potential relative risk factors are still need to further clarify.
Literature
1.
Armstrong DG, Peters EJ. Charcot’s arthropathy of the foot. J Am Podiatr Med Assoc. 2002;92:390–4.CrossRefPubMed
2.
Trieb K. The Charcot foot: pathophysiology, diagnosis and classification. Bone Joint J. 2016;98-B:1155–9.CrossRefPubMed
3.
Sanders LJ, Edmonds ME, Jeffcoate WJ. Who was first to diagnose and report neuropathic arthropathy of the foot and ankle: Jean-Martin Charcot or Herbert William Page? Diabetologia. 2013;56:1873–7.CrossRefPubMed
4.
La Fontaine J, Lavery L, Jude E. Current concepts of Charcot foot in diabetic patients. Foot (Edinb). 2016;26:7–14.CrossRef
5.
6.
Frykberg RG, Belczyk R. Epidemiology of the Charcot foot. Clin Podiatr Med Surg. 2008;25:17–28. vCrossRefPubMed
7.
Foltz KD, Fallat LM, Schwartz S. Usefulness of a brief assessment battery for early detection of Charcot foot deformity in patients with diabetes. J Foot Ankle Surg. 2004;43:87–92.CrossRefPubMed
8.
Strotman PK, Reif TJ, Pinzur MS. Charcot arthropathy of the foot and ankle. Foot Ankle Int. 2016;37:1255–63.CrossRefPubMed
9.
Rizzo P, Pitocco D, Zaccardi F, et al. Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2017;33: e2839.
10.
Folestad A, Alund M, Asteberg S, et al. Offloading treatment is linked to activation of proinflammatory cytokines and start of bone repair and remodeling in Charcot arthropathy patients. J Foot Ankle Res. 2015;8:72.CrossRefPubMedPubMedCentral
11.
Korzon-Burakowska A, Jakobkiewicz-Banecka J, Fiedosiuk A, et al. Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabet Med. 2012;29:771–5.CrossRefPubMed
12.
Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care. 2005;28:1214–5.CrossRefPubMed
13.
Hoche G, Sanders LJ. On some arthropathies apparently related to a lesion of the brain or spinal cord, by Dr J.-M. Charcot. January 1868. J Am Podiatr Med Assoc. 1992;82:403–11.CrossRefPubMed
14.
Schaper NC, Huijberts M, Pickwell K. Neurovascular control and neurogenic inflammation in diabetes. Diabetes Metab Res Rev. 2008;24(Suppl 1):S40–4.CrossRefPubMed
15.
Chisholm KA, Gilchrist JM. The Charcot joint: a modern neurologic perspective. J Clin Neuromuscul Dis. 2011;13:1–13.CrossRefPubMed
16.
Fauzi AA, Chung TY, Latif LA. Risk factors of diabetic foot Charcot arthropathy: a case-control study at a Malaysian tertiary care centre. Singap Med J. 2016;57:198–203.CrossRef
17.
Nobrega MB, Aras R, Netto EM, et al. Risk factors for Charcot foot. Arch Endocrinol Metab. 2015;59:226–30.CrossRefPubMed
18.
Chantelau E, Onvlee GJ. Charcot foot in diabetes: farewell to the neurotrophic theory. Horm Metab Res. 2006;38:361–7.CrossRefPubMed
19.
Mabilleau G, Petrova N, Edmonds ME, Sabokbar A. Number of circulating CD14-positive cells and the serum levels of TNF-alpha are raised in acute charcot foot. Diabetes Care. 2011;34:e33.CrossRefPubMedPubMedCentral
20.
Slowman-Kovacs SD, Braunstein EM, Brandt KD. Rapidly progressive Charcot arthropathy following minor joint trauma in patients with diabetic neuropathy. Arthritis Rheum. 1990;33:412–7.CrossRefPubMed
21.
Schinke T, Liese S, Priemel M, et al. Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J Bone Miner Res. 2004;19:2049–56.CrossRefPubMed
22.
23.
de Souza LJ. Charcot arthropathy and immobilization in a weight-bearing total contact cast. J Bone Joint Surg Am. 2008;90:754–9.CrossRefPubMed
24.
La Fontaine J, Harkless LB, Sylvia VL, Carnes D, Heim-Hall J, Jude E. Levels of endothelial nitric oxide synthase and calcitonin gene-related peptide in the Charcot foot: a pilot study. J Foot Ankle Surg. 2008;47:424–9.CrossRefPubMed
25.
Mascarenhas JV, Jude EB. The Charcot foot as a complication of diabetic neuropathy. Curr Diab Rep. 2014;14:561.CrossRefPubMed
26.
Munson ME, Wrobel JS, Holmes CM, Hanauer DA. Data mining for identifying novel associations and temporal relationships with Charcot foot. J Diabetes Res. 2014;2014:214353.CrossRefPubMedPubMedCentral
27.
Uccioli L, Sinistro A, Almerighi C, et al. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care. 2010;33:350–5.CrossRefPubMed
28.
Ndip A, Williams A, Jude EB, et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes. 2011;60:2187–96.CrossRefPubMedPubMedCentral
29.
Baumhauer JF, O'Keefe RJ, Schon LC, Pinzur MS. Cytokine-induced osteoclastic bone resorption in charcot arthropathy: an immunohistochemical study. Foot Ankle Int. 2006;27:797–800.CrossRefPubMed
30.
Paul RG, Bailey AJ. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol. 1996;28:1297–310.CrossRefPubMed
31.
Bluml S, Friedrich M, Lohmeyer T, et al. Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells. Ann Rheum Dis. 2015;74:227–33.CrossRefPubMed
32.
Sinacore DR, Bohnert KL, Smith KE, et al. Persistent inflammation with pedal osteolysis 1 year after Charcot neuropathic osteoarthropathy. J Diabetes Complicat. 2017;31:1014–20.
33.
Kucera T, Shaikh HH, Sponer P. Charcot neuropathic arthropathy of the foot: a literature review and single-center experience. J Diabetes Res. 2016;2016:3207043.CrossRefPubMedPubMedCentral
34.
Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest. 1993;92:212–7.CrossRefPubMedPubMedCentral
35.
Wukich DK, Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complicat. 2009;23:409–26.CrossRefPubMed
36.
Petrova NL, Shanahan CM. Neuropathy and the vascular-bone axis in diabetes: lessons from Charcot osteoarthropathy. Osteoporos Int. 2014;25:1197–207.CrossRefPubMed
37.
Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot’s osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia. 2008;51:1035–40.CrossRefPubMedPubMedCentral
38.
Jeffcoate W. Vascular calcification and osteolysis in diabetic neuropathy—is RANK-L the missing link? Diabetologia. 2004;47:1488–92.CrossRefPubMed
39.
Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795–823.CrossRefPubMed
40.
Byrne FR, Morony S, Warmington K, et al. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut. 2005;54:78–86.CrossRefPubMedPubMedCentral
41.
Bergamini A, Bolacchi F, Pesce CD, et al. Expression of the receptor activator of nuclear factor-kB ligand in peripheral blood mononuclear cells in patients with acute Charcot neuroarthropathy. Int J Med Sci. 2016;13:875–80.CrossRefPubMedPubMedCentral
42.
Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res. 1996;11:931–7.CrossRefPubMed
43.
Blakytny R, Spraul M, Jude EB. Review: the diabetic bone: a cellular and molecular perspective. Int J Low Extrem Wounds. 2011;10:16–32.CrossRefPubMed
44.
Kumar P, Rao GN, Pal BB, Pal A. Hyperglycemia-induced oxidative stress induces apoptosis by inhibiting PI3-kinase/Akt and ERK1/2 MAPK mediated signaling pathway causing downregulation of 8-oxoG-DNA glycosylase levels in glial cells. Int J Biochem Cell Biol. 2014;53:302–19.CrossRefPubMed
45.
Kim JH, Liu X, Wang J, et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis. 2013;5:13–31.CrossRefPubMedPubMedCentral
46.
Folestad A, Alund M, Asteberg S, et al. Role of Wnt/beta-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients. Acta Orthop. 2015;86:415–25.CrossRefPubMedPubMedCentral
47.
Agholme F, Macias B, Hamang M, et al. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. J Orthop Res. 2014;32:471–6.CrossRefPubMed
48.
Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24–33.CrossRefPubMed
49.
Molligan J, Barr C, Mitchell R, Schon L, Zhang Z. Pathological role of fibroblast-like synoviocytes in charcot neuroarthropathy. J Orthop Res. 2016;34:224–30.CrossRefPubMed
50.
Pitocco D, Zelano G, Gioffre G, et al. Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic charcot neuroarthropathy: a case-control study. Diabetes Care. 2009;32:1694–7.CrossRefPubMedPubMedCentral
51.
Petrova NL, Foster AV, Edmonds ME. Difference in presentation of charcot osteoarthropathy in type 1 compared with type 2 diabetes. Diabetes Care. 2004;27:1235–6.CrossRefPubMed
52.
Mascarenhas JV, Jude EB. Pathogenesis and medical management of diabetic Charcot neuroarthropathy. Med Clin North Am. 2013;97:857–72.CrossRefPubMed
53.
Nehring P, Mrozikiewicz-Rakowska B, Maroszek P, et al. Risk factors of charcot neuroarthropathy development in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2014;122:31–4.PubMed
54.
Stuck RM, Sohn MW, Budiman-Mak E, Lee TA, Weiss KB. Charcot arthropathy risk elevation in the obese diabetic population. Am J Med. 2008;121:1008–14.CrossRefPubMed
55.
Pakarinen TK, Laine HJ, Honkonen SE, Peltonen J, Oksala H, Lahtela J. Charcot arthropathy of the diabetic foot. Current concepts and review of 36 cases. Scand J Surg. 2002;91:195–201.CrossRefPubMed
56.
Milne TE, Rogers JR, Kinnear EM, et al. Developing an evidence-based clinical pathway for the assessment, diagnosis and management of acute Charcot neuro-arthropathy: a systematic review. J Foot Ankle Res. 2013;6:30.CrossRefPubMedPubMedCentral
57.
Jones CW, Agolley D, Burns K, Gupta S, Horsley M. Charcot arthropathy presenting with primary bone resorption. Foot (Edinb). 2012;22:258–63.CrossRef
58.
59.
Herbst SA, Jones KB, Saltzman CL. Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density. J Bone Joint Surg Br. 2004;86:378–83.CrossRefPubMed
60.
Sinacore DR, Hastings MK, Bohnert KL, et al. Inflammatory osteolysis in diabetic neuropathic (charcot) arthropathies of the foot. Phys Ther. 2008;88:1399–407.CrossRefPubMedPubMedCentral
61.
Pakarinen TK, Laine HJ, Maenpaa H, Kahonen M, Mattila P, Lahtela J. Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial. Foot Ankle Surg. 2013;19:121–4.CrossRefPubMed
62.
Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care. 2000;23:796–800.CrossRefPubMed
63.
Wukich DK, Raspovic KM, Suder NC. Prevalence of peripheral arterial disease in patients with diabetic charcot neuroarthropathy. J Foot Ankle Surg. 2016;55:727–31.CrossRefPubMed
64.
Aragon-Sanchez J, Lazaro-Martinez JL, Hernandez-Herrero MJ. Triggering mechanisms of neuroarthropathy following conservative surgery for osteomyelitis. Diabet Med. 2010;27:844–7.CrossRefPubMed
65.
Game FL, Catlow R, Jones GR, et al. Audit of acute Charcot’s disease in the UK: the CDUK study. Diabetologia. 2012;55:32–5.CrossRefPubMed
66.
Matricali GA, Bammens B, Kuypers D, Flour M, Mathieu C. High rate of Charcot foot attacks early after simultaneous pancreas-kidney transplantation. Transplantation. 2007;83:245–6.CrossRefPubMed
67.
Garcia Barrado F, Kuypers DR, Matricali GA. Charcot neuroarthropathy after simultaneous pancreas-kidney transplantation: risk factors, prevalence, and outcome. Clin Transpl. 2015;29:712–9.CrossRef
68.
Dehghani C, Russell AW, Perkins BA, et al. A rapid decline in corneal small fibers and occurrence of foot ulceration and Charcot foot. J Diabetes Complicat. 2016;30:1437–9.CrossRefPubMed
Metadata
Title
Pathogenesis and potential relative risk factors of diabetic neuropathic osteoarthropathy
Authors
Hong-Mou Zhao
Jia-Yu Diao
Xiao-Jun Liang
Feng Zhang
Ding-Jun Hao
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Orthopaedic Surgery and Research / Issue 1/2017
Electronic ISSN: 1749-799X
DOI
https://doi.org/10.1186/s13018-017-0634-8

Other articles of this Issue 1/2017

Journal of Orthopaedic Surgery and Research 1/2017 Go to the issue

Research article

A time-course microarray data analysis reveals consistent dysregulated genes and upstream microRNAs in autoantibody-mediated arthritis

Research article

Eight orthopedic surgeons achieved moderate to excellent reliability measuring the preoperative posterior tilt angle in 50 Garden-I and Garden-II femoral neck fractures

Research article

Fixation in slipped capital femoral epiphysis avoiding femoral-acetabular impingement

Review

The effect of midazolam on pain control after knee arthroscopy: a systematic review and meta-analysis

Research article

Weight-bearing recommendations after first metatarsophalangeal joint arthrodesis fixation: a biomechanical comparison

Research article

Evaluation of computed tomography post-processing images in postoperative assessment of Lisfranc injuries compared with plain radiographs